First Patient Enrolled in the Boston Scientific Multicenter Study of the SYNERGY™ Coronary Stent System Featuring a

   First Patient Enrolled in the Boston Scientific Multicenter Study of the
   SYNERGY™ Coronary Stent System Featuring a Bioabsorbable Polymer Coating

PR Newswire

NATICK, Mass., Nov. 30, 2012

NATICK, Mass., Nov. 30, 2012 /PRNewswire/ -- The first patient has been
enrolled in the Boston Scientific Corporation (NYSE: BSX) EVOLVE II clinical
trial, which is designed to further assess the safety and effectiveness of the
SYNERGY ^ Stent System and support U.S. Food and Drug Administration and
Japanese regulatory approvals for the treatment of atherosclerotic coronary
lesions. Boston Scientific received CE Mark approval for the SYNERGY Stent
System last month. The EVOLVE II clinical program is anticipated to enroll
approximately two thousand patients at up to 160 sites worldwide including the
United States, Canada, Europe, Australia, New Zealand, Japan, India, Brazil
and Singapore. The first patient was enrolled at the Christ Hospital, Lindner
Research Center in Cincinnati, Ohio. The SYNERGY Stent uses the
market-leading everolimus drug and features an ultra-thin bioabsorbable
polymer coating. The absorption of the polymer is completed shortly after
drug elution ends at three months.

"SYNERGY is the most flexible, conformable and deliverable drug eluting stent
platform that I have ever deployed," said Dean Kereiakes, M.D., F.A.C.C.,
Christ Hospital and the principal investigator of the study.  "I am
enthusiastic about its potential impact on patient care since the SYNERGY
System was designed to reduce the risk of late adverse events and the need for
prolonged dual antiplatelet therapy, which is often associated with a higher
risk of bleeding, as well as increased cost."

The EVOLVE II clinical trial builds upon the EVOLVE study. EVOLVE was a
prospective, randomized, single-blind, first human use study comparing the
SYNERGY Stent to the PROMUS Element Stent, which uses a durable polymer
coating. Outcomes with the SYNERGY Stent in EVOLVE were comparable to
outcomes with the PROMUS Element Stent at six months and one year.

"We continue to strengthen our drug-eluting stent portfolio with innovations
like the SYNERGY System in an effort to increase the advanced treatment
options available to physicians and patients," said Kevin Ballinger, president
of Interventional Cardiology at Boston Scientific. "This underscores our
commitment to the drug-eluting stent market and reinforces our position as a
global market leader."

Patients enrolled in the EVOLVE II trial will be followed for five years. The
SYNERGY Stent System is an investigational device in non-CE Mark countries and
is not available for sale in the United States and Japan.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices that are used in a broad range of interventional medical
specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements may be identified by words
like "anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are based on our
beliefs, assumptions and estimates using information available to us at the
time and are not intended to be guarantees of future events or performance.
These forward-looking statements include, among other things, statements
regarding regulatory approvals, clinical trials, product performance and
importance, and competitive offerings. If our underlying assumptions turn out
to be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect our
ability to implement our business strategy and may cause actual results to
differ materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue reliance
on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future
economic, competitive, reimbursement and regulatory conditions; new product
introductions; demographic trends; intellectual property; litigation;
financial market conditions; and future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A – Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A – Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our expectations or in
events, conditions or circumstances on which those expectations may be based,
or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this document.

CONTACT: Steven Campanini
            508-652-5740 (office)
            Media Relations
            Boston Scientific Corporation
            Michael Campbell
            508-650-8023 (office)
            Investor Relations
            Boston Scientific Corporation

SOURCE Boston Scientific Corporation

Press spacebar to pause and continue. Press esc to stop.